Advertisement
SomaLogic has generated novel aptamers that target over 500 humanproteins. These aptamers have very high affinity and specificity. As part ofthis collaboration, Otsuka will have access to this growing resource fortarget validation, drug screening and other assays to accelerate theirdevelopment of new therapeutics. In addition, Otsuka will have access toSomaLogic's highly multiplexed proteomic arrays to facilitate the discoveryand monitoring of biomarkers in support of Otsuka's clinical programs andtherapeutic products.
Advertisement
"We are very pleased to have Otsuka as a collaborator," stated Dr. LarryGold, CEO of SomaLogic. "Otsuka's broad vision for global healthcare willhelp us achieve our goal of using aptamer technology to transform medicine.Otsuka believes deeply in the SomaLogic paradigm through which early detectionand proper diagnosis of disease leads to both pharmaceutical and nutritionalintervention and better health."
About Aptamers
Aptamers are single-stranded nucleic acids that form well-definedthree-dimensional shapes, allowing them to bind target molecules in a mannerthat is conceptually similar to antibodies. Aptamers combine the optimalcharacteristics of small molecules and antibodies, including high specificityand affinity, chemical stability, and the ability to target protein-proteininteractions. In contrast to monoclonal antibodies, aptamers are chemicallysynthesized, rather than biologically expressed, and may offer significantmanufacturing advantages.
About SomaLogic
SomaLogic, Inc. is a privately-held biomarker discovery and clinicalproteomics company based in Boulder, Colorado. The company's mission is touse its proprietary aptamer technology to develop aptamers with remarkableaffinity and specificity for their molecular targets, and to develop enhancedprotein analysis tools and reagents for the life sciences community.SomaLogic is developing and commercializing clinical diagnostic products thatwill improve the delivery of healthcare by offering timely and accuratediagnostic information to physicians and their patients.
SomaLogic's aptamer expertise is complemented by a robust patent estatecomprised of over 220 issued and 230 pending patents covering theidentification, composition, and use of diagnostic aptamers. In addition tothe company's core aptamer generation technology, SomaLogic possesses deepexpertise in the use and development of aptamer arrays for biomarkerdiscovery, life sciences research, and clinical diagnostics.
Further information about SomaLogic can be found athttp://www.somalogic.com.
Direct contact can be arranged through [email protected] or through AnneWong at [email protected].
About Otsuka Pharmaceutical Co., Ltd.
Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcarecompany with the corporate philosophy: 'Otsuka -- people creating new productsfor better health worldwide.' Otsuka researches, develops, manufactures andmarkets innovative and original products, with a focus on pharmaceuticalproducts for the treatment of diseases and consumer products for themai
